scholarly journals Health Economic Evaluations in Inflammatory Bowel Disease in Brazil: A Systematic Review

2017 ◽  
Vol 20 (9) ◽  
pp. A636
Author(s):  
TC Decimoni ◽  
S Sztajnbok ◽  
AC Moraes
2019 ◽  
Vol 25 (9) ◽  
pp. 1462-1473 ◽  
Author(s):  
Abhinav Vasudevan ◽  
Peter R Gibson ◽  
Daniel R Van Langenberg

Abstract Background Medication costs in inflammatory bowel disease (IBD) are now the principal driver of health care costs. Cost-effective strategies to optimize and rationalize treatment are therefore necessary. Methods A systematic review until April 30, 2018, was performed to identify economic evaluations of strategies to optimize infliximab, adalimumab, and immunomodulators for the treatment of IBD in adults. A qualitative synthesis of the identified studies was performed. Results Seventy articles were identified that met the inclusion criteria. Adalimumab seems cost-effective compared with infliximab as maintenance therapy for moderate to severe Crohn’s disease (CD). Infusion costs are a significant additional treatment cost with infliximab. However, other studies found biosimilar infliximab more cost-effective than alternative biologics in fistulizing and moderate-severe luminal CD—although the latter did not reach a willingness-to-pay threshold of <$50,000. In moderate-severe ulcerative colitis, infliximab seems more cost-effective than adalimumab. Multiple tailored approaches to treatment based on objective markers of disease activity or efficacy have been shown to be cost-effective in CD, including following secondary loss of response to anti-TNF therapy for postoperative recurrence and in escalating treatment. For immunomodulator treatment, both thiopurine methyltransferase (TPMT) testing before commencing thiopurines and thiopurine metabolite testing for dose optimization seem cost-effective. Conclusion In a win-win for patients and payers, several potential avenues to achieve cost-effectiveness—but also therapeutic optimization of anti-TNF therapies—were elucidated in this review with comparatively sparse data for immunomodulators. Optimizing immunomodulator and anti-tumor necrosis factor alpha therapy to achieve objective disease control seems to be cost-effective at conventional willingness-to-pay thresholds in a number of clinical settings.


2021 ◽  
Vol 160 (6) ◽  
pp. S-357
Author(s):  
Jalpa Patel ◽  
Dina Fakhouri ◽  
Mohamed Noureldin ◽  
Iris Kovar-Gough ◽  
Francis A. Farraye ◽  
...  

Author(s):  
Ryusuke Nambu ◽  
Neil Warner ◽  
Daniel J. Mulder ◽  
Daniel Kotlarz ◽  
Dermot P.B. McGovern ◽  
...  

2018 ◽  
Vol 154 (6) ◽  
pp. S-371
Author(s):  
Ramprasad Jegadeesan ◽  
Madhav Desai ◽  
Tharani Sundararajan ◽  
Venkata Subhash Gorrepati ◽  
Viveksandeep Thogulva Chandrasekar ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document